Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Daiichi Sankyo Inc has filed a supplemental new drug application with the FDA for cholesterol drug WelChol to improve glycemic control in patients with type 2 diabetes.
Subscribe to our email newsletter
The US subsidiary of Japanese pharmaceutical company Daiichi Sankyo said that, if approved, WelChol will be the first LDL cholesterol-lowering medication also indicated for improving glycemic control.
Clinical studies have shown that WelChol lowers A1C in patients with type 2 diabetes mellitus, according to the company, including one recently presented at the American Heart Association’s Scientific Sessions 2006 in Chicago.
Joseph Pieroni, president and CEO of Daiichi Sankyo Inc, said: “Given the prevalence of type 2 diabetes and high cholesterol and the number of patients who are not reaching goal, adding WelChol expands patients’ treatment options.”